Résultats de la recherche
10
Tout
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
13 janv. 2025 08h00 HE
|
Immuneering Corporation
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
ONCOTELIC TO PARTICIPATE AT THE ASCO 2024 MEETING
20 mai 2024 08h10 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its Chief Clinical Officer- Dr. Anthony Maida will be participating at the ASCO 2024...